Table 3.

Select patient demographics and baseline disease characteristics for patients who did or did not receive first subsequent CT in PALOMA-3 by treatment arm.

	Without First Subsequent CT		With First Subsequent CT
	PAL + FUL	PBO + FUL	PAL + FUL	PBO + FUL
	(n = 204)	(n = 86)	(n = 143)	(n = 88)
Age, median, y	58.0	60.0	56.0	54.0
< 65 y, n (%)	145 (71.1)	64 (74.4)	116 (81.1)	67 (76.1)
≥ 65 y, n (%)	59 (28.9)	22 (25.6)	27 (18.9)	21 (23.9)
Race,*n (%)
White	150 (73.5)	68 (79.1)	102 (71.3)	65 (73.9)
Black	8 (3.9)	4 (4.7)	4 (2.8)	4 (4.5)
Asian	40 (19.6)	14 (16.3)	34 (23.8)	17 (19.3)
Other	6 (2.9)	0	2 (1.4)	1 (1.1)
Unspecified	0	0	1 (0.7)	1 (1.1)
Weight, median, kg	67.1	71.2	69.0	68.4
Menopausal status, n (%)
Premenopausal/perimenopausal	39 (19.1)	10 (11.6)	33 (23.1)	26 (29.5)
Postmenopausal	165 (80.9)	76 (88.4)	110 (76.9)	62 (70.5)
Disease site, n (%)
Visceral	109 (53.4)	43 (50.0)	91 (63.6)	61 (69.3)
Nonvisceral	95 (46.6)	43 (50.0)	52 (36.4)	27 (30.7)
Sensitivity to prior ET, n (%)
Yes	162 (79.4)	65 (75.6)	111 (77.6)	68 (77.3)
No	42 (20.6)	21 (24.4)	32 (22.4)	20 (22.7)
Prior CT for primary diagnosis, n (%)
No	59 (28.9)	17 (19.8)	35 (24.5)	19 (21.6)
Yes	145 (71.1)	69 (80.2)	108 (75.5)	69 (78.4)
Neoadjuvant	41 (20.1)	15 (17.4)	26 (18.2)	18 (20.5)
Adjuvant	87 (42.6)	48 (55.8)	64 (44.8)	41 (46.6)
Metastatic	62 (30.4)	26 (30.2)	51 (35.7)	38 (43.2)
Missing	0	1 (1.2)	1 (0.7)	0
Prior hormonal therapy, n (%)
1	78 (38.2)	37 (43.0)	48 (33.6)	34 (38.6)
> 1	126 (61.8)	49 (57.0)	95 (66.4)	54 (61.4)
Metastatic	151 (74.0)	64 (74.4)	108 (75.5)	64 (72.7)
Prior lines of therapy for ABC, n (%)
0/1	135 (66.2)	61 (70.9)	80 (55.9)	63 (71.6)
≥ 2	69 (33.8)	25 (29.1)	63 (44.1)	25 (28.4)

ABC = advanced breast cancer; CT = chemotherapy; ET = endocrine therapy; FUL = fulvestrant; PAL = palbociclib; PBO = placebo.

*Other includes not reported/missing patients.